News

The Dotmatics platform is a fully optimized suite of programs designed to make research data readily accessible and useful. The company’s suite of solutions are used to manage

The model-based approach links drug process and product engineering to product quality and performance in the human body. Pfizer senior research fellow, keynote speaker Ravi Shanker said it

The randomized, open-label study is designed to evaluate the safety and efficacy of the novel combination therapy. The multicenter trial will enroll a total of 100 patients in

The AlpVision’s patented Fingerprint technology is used in the partnership, which enables brand owners in the pharmaceutical industry to track and validate mass produced products manufactured in a

The antineoplastic agent of the topoisomerase I inhibitor class, in combination with 5-fluorouracil and leucovorin, is indicated for patients with metastatic carcinoma of the colon or rectum whose

The Phase 3 study is a randomized-withdrawal placebo-controlled trial included three phases: an open-label phase, during which the optimized 100-250mg two times per day dose of tapentadol ER

The study will evaluate the company’s NVC-422, to treat adenoviral conjunctivitis, a highly contagious form of pink eye. This global study is expected to enrol approximately 450 patients

EP-100 is a targeted membrane-disrupting peptide designed to search for and destroy cancer cells that over-express luteinizing hormone releasing hormone receptors on their surfaces. The randomized, multi-center trial

The preclinical findings also demonstrate that CEP-32496 possesses potent and sustained anti-tumor activity in xenograft models of melanoma and colon carcinoma. CEP-32496 possesses attractive pharmacokinetic properties upon oral